Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of PRM-151 in idiopathic pulmonary fibrosis
MOH_2021-01-02_009622Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing PRM-151 arm with Placebo arm (2 arms). Primary endpoint: Absolute change from baseline to Week 52 in forced vital capacity. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
zinpentraxin alfa
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on MOH_2021-01-02_009622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-02_009622.